/ /

  • linkedin
  • Increase Font
  • Sharebar

    Innovation in glaucoma thriving

    New drugs, devices, diagnostics ‘nicely’ fueling growth


    Drug delivery

    Drug delivery is a weak point in glaucoma treatment. Eye drops work, but only if used properly. And adherence falls precipitously to well below 50% for most topical glaucoma agents within the first six months.

    “Developing sustained-release drug delivery is important,” Dr. Cunningham said. “Punctal plugs have moved into phase II trials with latanoprost.”

    What began as a 1.45-mm punctal plug from ForSight has moved to QLT to Matai Therapeutics. The initial design has been re-engineered so that the plug is better retained in the punctum.

    Ocular Therapeutix is moving forward with its own punctal plug loaded with travoprost. The company plans to launch a 90-day phase IIb trial later this year.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results